26 October 2018 | News
Under the agreement both companies will evaluate the solid tumor responses to various novel combination therapies and dosing seen with Trethera's compound TRE-515.
Image credit- oncologycentral.com
Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, and KYAN Therapeutics, an artificial intelligence-based drug development firm, announced an agreement to collaborate on preclinical studies evaluating up to four different tumor types beginning this year leveraging their unique expertise to develop best-in-class combination therapies addressing unmet needs in solid tumors.
Under the agreement both companies will evaluate the solid tumor responses to various novel combination therapies and dosing seen with Trethera's compound TRE-515. It is a first-in-class preclinical drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the deoxyribonucleoside salvage pathway, one of two biosynthetic pathways that generate the DNA precursors, the other being the de novo pathway.
KYAN was initiated by a team of visionary leaders from NUS and UCLA that has successfully taken its proprietary portfolio of AI platforms through clinical validation.